XENE Q4 2018 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+37400.0% YoY

Gross Profit

-$402,000-6.7% margin

Operating Income

-$8M-140.6% margin

Net Income

-$9M-142.6% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$575,000

Balance Sheet

Total Assets

$122M

Total Liabilities

$19M

Stockholders' Equity

$103M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$16,000	+37400.0%
Gross Profit	-$402,000	-$6M	+93.7%
Operating Income	-$8M	-$8M	-4.8%
Net Income	-$9M	-$8M	-6.1%